Clinical Trial

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial tests how well immunotherapy (toripalimab) works for reducing the risk of cancer recurrence after surgery in patients with mismatch repair deficient stage IIB, IIC, or III colon cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-22; most recent amendment 2025-09-23.
Status change: Not Yet Recruiting → Recruiting 2025-09-23
Trial Details
NCT Number NCT07140679
Lead Sponsor Emory University
Collaborators: National Cancer Institute (NCI), Coherus Oncology, Inc.
Conditions Localized Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage III Colon Cancer AJCC v8
Enrollment 40 participants
Start Date 2025-09-19
Primary Completion 2029-09-30 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-25